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AICAR (Acadesine) is a pharmacological precursor of purine nucleotide biosynthesis with anti-tumoral properties.
Although recognized as an AMP mimetic activator of the protein kinase AMPK, the AICAR monophosphate
derivative ZMP was also shown to mediate AMPK-independent effects. In order to unveil these AMPK-
independent functions, we performed a transcriptomic analysis in AMPKα1/α2 double knockout murine embryonic
cells. Kinetic analysis of the cellular response to AICAR revealed the up-regulation of the large tumor suppressor kinases
(Lats) 1 and 2 transcripts, followed by the repression of numerous genes downstream of the transcriptional regulators
Yap1 and Taz. This transcriptional signature, together with the observation of increased levels in phosphorylation of
Lats1 andYap1 proteins, suggested that theHippo signalingpathwaywas activated byAICAR. This effectwasobserved
in both fibroblasts and epithelial cells. Knockdown of Lats1/2 prevented the cytoplasmic delocalization of Yap1/Taz
proteins in response toAICAR and conferred a higher resistance to the drug. These results indicate that activation of the
most downstream steps of the Hippo cascade participates to the antiproliferative effects of AICAR.
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AICAR (5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) is
a pharmacologically active compound entering cells via purine
transporters and being converted to its active-monophosphorylated
form ZMP by adenosine kinase [1,2]. ZMP mimics AMP as a
low-energy charge signal by activating the heterotrimeric
AMP-activated protein kinase (AMPK), which promotes integrated
regulatory functions at the cellular and tissular levels [3].
In mammal cells, an AICAR-induced cytotoxic response is observed,
leading to both apoptotic and non-apoptotic death mechanisms [4–8].
Interestingly, AICAR is more cytotoxic for aneuploid cells compared to
their euploid counterparts [6,9], which is of a great therapeutic interest
since aneuploidy is observed in human in 90% of solid tumors and 85%
of hematopoietic malignancies [10]. Moreover, AICAR showed
antitumoral properties in vivo in different animal models [6,11,12]
and is well tolerated in mice and human, even at elevated and repeated
administration doses [13,14]. AICAR has been subjected to Phase I/II
clinical trials for treating chronic lymphocytic leukemia [14].Although AMPK activation has been initially recognized as a
prevalent effect of AICAR, recent data indicated that many effects
mediated by this compound are in fact AMPK-independent. These
include inhibition of proliferation and limited tumor growth in vivo
556 Activation of the Hippo Pathway by AICAR Philippe et al. Neoplasia Vol. 20, No. xx, 2018[2,5,15–17]. These intriguing properties of AICAR therefore
motivate the search for alternative targets of its metabolic derivative
ZMP that could be exploited therapeutically.
In order to get further insight on the AMPK-independent action of
AICAR, we carried out a kinetic analysis of the effects of AICAR on
the transcriptome changes in murine embryonic fibroblasts (MEFs)
invalidated for AMPK (α1 and α2 subunits) [18]. We identified
Lats1 and Lats2 as early AICAR-induced genes and showed that the
encoded proteins (herein referred as to Lats1/2) are potent mediators
of the cell response to this drug. Lats1/2 proteins are downstream
transducers of the core Hippo pathway known to play a pivotal role in
cells and tissues [19,20]. Lats1/2 display pleiotropic functions, which
include the inhibition of the two related co-transcriptional factors
Yap1 (Yes-associated protein 1) and Taz (Transcriptional coactivator
with PDZ-binding motif). Knockdown of Lats1/2 established that
some of the cellular effects triggered by AICAR result of the activation
of this central pathway controlling cell cycle and density. These
findings provide a rationale to analyze the effects of AICAR and
motivate the research of derivatized compounds of AICAR with
therapeutic perspectives.Materials and Methods
Reagents
Culture media was from Invitrogen. Specific antibodies were as
follows: Taz (#560235) (BD Pharmingen); actin (#A2668) (Sigma);
AMPKα (#2532), PARP (#9542), LATS2 (#13646), LATS1
(#3477), phospho-(Thr1079)-LATS1 (#8654), LC3A/B (#4108),
cleaved-(Asp175)-caspase-3 (#9604 and 9664), YAP1/TAZ (#8418),
YAP1 (#14074 and #4912), phospho-(Ser127)-YAP1 (phospho-(-
Ser112)-Yap1 in mice) (#4911) were from Cell Signaling; LATS2
(#NB200–199, NovusBio); DAPI and secondary antibodies labeled
with AlexaFluor488 or with AlexaFluor555 were from ThermoFisher
Scientific. Primers (Table S1) and siRNA (see below) were from
Sigma. Control siRNA was from Cell Signaling (#6568). AICAR
(#A611700, Toronto Research Chemicals, Canada) was solubilized in
water and filtered at 0.22 μm. Its concentration was determined
spectrophotometrically (A269; pH = 7; εM = 12,700 M
−1/cm−1).
Cell Culture
Human RPE-1 (ATCC; CRL-4000) cells were grown in DMEM,
4.5 g/L glucose supplemented with 10% FBS, 2 mM L-glutamine,
100 U/ml penicillin and 100 μg/ml streptomycin. Wild-type and
knock-out mouse embryonic fibroblasts (MEFs) for both AMPKα1
and AMPKα2 subunits (MEF-dKO) were obtained from the
U1016-INSERM, Paris (Laderoute et al. [18]) and the absence of
AMPKα in MEF-dKO was confirmed by Western blot (see text). The
WST-1 cell viability assay was performed in 96-well plates as previously
described [2]. Cell proliferation assays were performed in 24-well plates
and cells were counted using aMultisizer 4 Coulter Counter (Beckman).
Each time point was done in triplicate, and the averages ± STD were
calculated. Experiments were repeated three times.
Preparation of cRNA, Microarray Hybridization and Gene
Expression Profiling
Microarray analysis was performed at the Affymetrix transcriptome
Platform, CHRU-Inserm U1040, Montpellier France (http://www.
chu-montpellier.fr/fr/irmb/). MEF-dKO were grown in complete
DMEM medium in the presence or absence of 1 mM AICAR andharvested at the indicated times (Final density ~15,000 cells/cm2).
Total RNA was extracted using the RNeasy kit (Qiagen, Santa
Clarina, CA) and the quality of each sample was assessed on a
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA).
Affymetrix Gene Chip 3`IVT Express Kit Bundle was used to generate
amplified RNA. cRNAs were hybridized to Mouse MG-430 PM Array
Strip Kit (44,000 probesets). All steps were performed according to the
standard protocol of the manufacturer. Fluorescence intensities were
quantified and analyzed using the Expression Console v 1.2 software.
The converted digital intensity values were then converted into cell
intensity files using the AffymetrixGeneAtlas Software. The fold change
in gene expression corresponds to the ratio between each incubation
times with AICAR and control without AICAR. Significance analysis of
microarrays (SAM) analysis was applied in the different samples with
400 permutations, a fold change of 2 and a false discovery rate (FDR) b
3.55% (see Table S2A). All steps were conducted according to the
MIAME (Minimum Information About a Microarray Experiment)
checklist [21]. Annotation of genes was performed using NetAffx
(http://www.affymetrix.com). Affymetrix IDs were submitted to the
DAVID analysis tool (http://david.abcc.ncifcrf.gov/home.jsp), the
Netaffx Analysis Center (https://www.affymetrix.com/analysis/com-
pare/index.affx) and the KEGG pathway database (www.genome.jp/
kegg/pathway.html) to depict biological processes associated with the
functions of regulated genes. Data files were deposited in the Gene
Expression Omnibus (GEO) database (accession number,
GSE106460; www.ncbi.nlm.nih.gov/geo).
Small Interfering RNA Knockdown
Cells were plated at a density of 5.104 cells per well in six-well plates.
Small interfering RNA (siRNA) against human and mouse LATS1
(sihmLATS1): CACGGCAAGAUAGCAUGGAUU; human and
mouse LATS2 (sihmLATS2-y): GAAGAUUGUAUUUAUG
GUAAA; mouse AMPKα1/2_human AMPKα2 (simAMPKα1/2
sihAMPKα2): GAGAAGCAGAAGCACGACG; human AMPKα1
(sihAMPKα1): AUGAUGAAAUUACAGAAGCCA were from
Sigma. Non-targeting siRNA (#D-001810-01-20) was fromDharmacon
(Lafayette, CO). Transfection was performed for 6–15 h using
lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's
protocol, with total amounts of siRNA at a final concentration of
10–60 nM, as indicated in the figure legends.
Immunoblot
Cells in culture dishes were collected using a rubber policeman and
snap frozen. Proteins were extracted at 4°C with RIPA buffer
containing phosphatase inhibitors (PhosStop EasyPack, ROCHE)
and protease inhibitors (Complete ULTRA Tablets, mini EasyPack,
ROCHE). Protein content was determined by using a BCA protein
assay kit (Pierce). Proteins were resolved on 7 or 10% SDS-PAGE,
transferred to a PVDF blotting membrane (Hybond P 0.45 μm
PVDF membrane; Amersham) and probed using primary antibodies.
Secondary antibodies coupled to HRP were used for revelation.
Densitometric analyses were carried out using ImageJ (http://rsbweb.
nih.gov/ij/download.html) and results were normalized to the actin
loading control.
Real-Time PCR
Cells in culture dishes were solubilized in Trizol (Life Technol-
ogies) and frozen at −80°C until use. RNA extraction, quantification
and gene expression analyses by RT-qPCR were performed as
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HPRT1. Results were the mean of triplicate determinations ± SD.
Immunofluorescence
MEFs and RPE-1 cells were seeded at the density of 7,000 cells/cm2
on 18-mm glass coverslips N° 1.5H (Marienfeld, Germany). After one
day of incubation, cells were washed and incubated with AICAR for the
indicated times. They were then washed with PBS, fixed for 20 min
with 4%paraformaldehyde in PHEM, permeabilized with 0.1%Triton
X-100 in PBS and blocked in 0.1% BSA in PBS for 15 min. Cells were
then incubated first for 60 min at 37°C in the blocking buffer
containing anti-Yap1 or anti-Taz antibodies, followed by incubation
with AlexaFluor 488-labeled anti-rabbit antibodies (Yap1) or
AlexaFluor 555-labeled anti-mouse antibodies (Taz). Nuclei were
counter-stained with DAPI. Microphotographs were obtained using an
Olympus Ix81 inverted microscope (Olympus, Rungis, France) with a
40× oil immersion objective, NA 1.3. Image analyses were carried out
using ImageJ free software. Statistical analyses were based on the
quantification of the fluorescent signal on at least 10 different fields
(N50 cells per condition).Results
AMPK-Independent Transcriptional Response to AICAR in
MEF-dKO
In order to get a dynamic view of the transcriptomic response to
AICAR, a 24-h kinetic analysis was carried out inMEF-dKOAMPK in
the presence of 1 mM AICAR, a condition resulting in robust ZMP
accumulation in both MEF-dKO and MEF-wt (Figure S1). We
observed that the absence of AMPK did not significantly affect the
propagation of MEFs in standard culture conditions (Figure S2A).
However, the MEF-dKO were slightly more sensitive than MEF-wt to
the highest dose of the drug, as monitored by using a cytotoxic assay
(Figure S2, B and C) and analyses of the apoptotic process using
standard procedures (Figure S2, D and E). By assessing the
transcriptome across seven time points in MEF-dKO (Figure 1A),
significance analysis of microarray (SAM) revealed that 1325 probesets
(1071 genes; 19.1% redundancy), corresponding to ~2.9% of the total
number of the probesets available on the chips, were AICAR-responsive
(minimum2-fold change; FDR (%) b 3.55, values given inTable S2A).
The number of genes modulated under AICAR treatment increased
with time (Figure 1B). A majority of genes were down regulated at early
times (100% at t = 1 h), while a similar number of genes were up- and
down- regulated from 8 to 24 h of incubation. The variation of gene
expression pattern indicated that 627 AICAR-responsive probesets
(47.3%)were consistently up-regulated overtimewhereas 697 probesets
(52.6%) were strictly down-regulated (Table S2A).
An early and sustained up-regulation of transcripts encoding the
large tumor suppressor proteins Lats1 and Lats2 was detected along
the time-course experiment (Figure 1C). Lats1/2 are protein kinases
and members of the Hippo pathway core, which is critically involved
in mammals in several processes including growth inhibition,
survival, epithelial to mesenchymal transition and the response to
stressors. A major Hippo signaling outcome is the inhibition by
Lats1/2 of the two highly related oncoproteins Yap1 (Yes-associated
protein 1) and Taz (transcriptional co-activator with PDZ-binding
motif) [19,20]. We therefore questioned the possible impact of
AICAR on the transcriptional activities of Yap1 and Taz. Comparison
of transcriptome signatures in human cells overexpressing YAP1 orTAZ [23] with transcripts responding to AICAR revealed an overlap
of ~200 genes. Notably, most of these genes were detected lately (12
and 24 h) upon AICAR treatment, well after the onset of Lats1/2
up-regulation (Figure 1C). Several of these genes, including Ccnd1,
Ctgf, Cyr61, Irs1 and Thbs1 (Figure C and Table S2A) are
well-recognized Hippo targets [24–26]. Further combination of
literature and data mining established an expandable common gene
signature of AICAR and Yap1/Taz, currently representing ~19% of
the total number of genes regulated by AICAR (Table S2B). The extent
of this overlap is likely underestimated here, since comparisons were
carried out between mice (AICAR signature) and human (YAP1/TAZ
signatures), the gene symbol attribution being somewhat different in the
two organisms. The GO-term enrichment profile of AICAR-responsive
genes predominantly points to the regulation of gene expression,
nucleotide binding andmRNA processing (Table S3). Of note, AICAR
treatment could also have concurrent effects on cell proliferation by the
coordinate inhibition of several genes functionally linked to the
epidermal growth factor (EGF) and to the insulin/insulin-like growth
factor (IGF) signaling pathways (Table S4). Repression of several of
these genes is expected to contribute to the inhibition of Yap1/Taz
functions [27,28]. Most of these events occurred later in time and are
likely subordinated to primary events triggered by AICAR. Overall,
analysis of the gene-expression profile pointed to the Hippo signaling
pathway as a major target of AICAR in MEF-dKO (Figure 1D).
The Hippo Pathway is Activated Under AICAR Treatment
RT-PCR analysis validated the fact that Lats1 and Lats2 mRNAs
were increased in MEF-dKO in response to AICAR (Figure 2A).
These effects were associated to the progressive decrease in the level of
both Cyr61 and Ctgf transcripts, two surrogate markers of Hippo
pathway activation and Yap1/Taz inhibition. Importantly, these
effects were found whether AMPK was present or not, i.e. in both
MEF-dKO and MEF-wt (Figure 2A).
Lats1/2 protein levels were also increased after 4 h of incubation in
the two isogenic cell lines as measured by Western blot (Figure 2, Ba
and Ca). Activation of the Hippo pathway under AICAR treatment
was further confirmed by the increased phosphorylation of the
proteins Lats1/2 using an antibody directed against
phospho-(Thr1079)-LATS1 that also partially cross-reacts with
p-LATS2 (Figure 2, Ba and Ca). Phosphorylation of Lats1/2 was
accompanied in both cell lines by the increase of Yap1 phosphor-
ylation (p-S112-Yap1) (Figure 2, Bb and Cb), a marker of Yap1
inhibition by Lats1/2 [19,20]. The total amounts of Yap1 and Taz
proteins were also increased under AICAR treatment, in agreement
with results obtained by others in HepG2 cells [29]. Thus, Lats1/2
were up-regulated at both the mRNA and protein levels upon AICAR
treatment, and this effect was associated with their activating
phosphorylation. These events did not require the presence of
AMPK, as they were observed in both MEF-dKO and MEF-wt cells.
AICARTreatment PromotedNuclearDelocalization of YAP1/TAZ
One reported consequence of the activation of the Hippo pathway
is the nuclear exclusion of YAP1/TAZ [19,20]. Hence, we performed
immunofluorescence analyses on MEF-wt and MEF-dKO subjected
or not to AICAR treatment. As shown in Figure S3, A-B, both Yap1
and Taz immunoreactivities were predominantly nuclear in control
conditions. Besides, a modest but reproducible delocalization of the
signal (b 50%) was measured in these cells at different incubation
times with AICAR. We considered that this limited nuclear exclusion
Figure 1. Gene expression analysis highlights the up-regulation of Lats1/2 under AICAR treatment. Gene profiling analyses were
performed in murine embryonic fibroblasts that have been invalidated for the two catalytic subunits of the AMPK (MEF-dKO). The kinetic
of AICAR-mediated gene expression was obtained from cells stimulated or not with 1 mM AICAR. Functional annotation clustering was
performed by using Netaffx Analysis Center (Affymetrix database) as well as the DAVID Bioinformatics Resources v6.8. (A) General
schematic of the procedure that led to a focus on the up-regulation of Lats1/2 transcripts. (B) Histogram representation of the number of
genes Up- and Down-regulated as a function of time. (C) Early up-regulation of Lats1/2 mRNA in response to AICAR treatment, and late
repression of reporters of Yap1/Taz nuclear functions. Values indicate the fold-increases associated with AICAR treatment. (D) Schematic
depicting the model of a two-wave effect of AICAR on the gene expression pattern in MEF-dKO: Lats1 and Lats2 transcripts increased
(UP) after 2 h of treatment with AICAR, and the Yap1/Taz-type signature (DOWN) was essentially observed at times 12 h and 24 h.
558 Activation of the Hippo Pathway by AICAR Philippe et al. Neoplasia Vol. 20, No. xx, 2018of Yap1/Taz in MEFs could be the consequence of the cellular
immortalization by SV40 large T antigen [18], the Hippo pathway
being perverted by viral oncoproteins [30,31]. We therefore designed
a control experiment based on the well-described subcellular
delocalization of YAP1 in cell–cell contact condition at high cell
density [26]. Strikingly, endogenous signals associated to a high cell
density did not lead either to a substantial delocalization of Yap1 in
immortalized MEFs, whereas a robust translocation was observed in
human retinal epithelial (RPE-1) cells (Figure S3C). In keeping with
this, we observed that primary cultured MEF readily responded to
AICAR treatment by the unambiguous decrease of both Yap1 and Taz
immunoreactivities in the nuclear compartment (Figure S3D). Thus,
subcellular delocalization of Yap1/Taz under AICAR treatment wasreadily observed in primary cultured MEFs and was attenuated in
SV40-immortalized MEFs. Noticeably, inhibition of Yap1 in immor-
talized MEFs was dissociated from its complete cytoplasmic
translocation.
The effect of AICAR on the Hippo pathway was indeed confirmed
in RPE-1 cells. AICAR induced a time-dependent redistribution of
YAP1 and TAZ from the nucleus to the cytoplasm (Figure 3, A and
B) due to a rapid (t b 4 h) decrease of the corresponding signals in the
nucleus. This effect was followed by their late (t N 8 h) extinction in
the cytosol (Figure 3B). A higher expression of LATS1 protein was
consistently observed after 4 h of treatment (Figure S4A). Overall,
these results indicated that AICAR regulates YAP1/TAZ subcellular
localization in polarized epithelial cells as well as in fibroblasts.
Figure 2. AMPK-independent activation of the Hippo pathway under AICAR treatment. RT-qPCR and Western blot analyses of MEF-wt
and MEF-dKO. Exponentially growing cells were stimulated or not with AICAR for different times and cell extracts were subjected to
RT-qPCR or to Western blot analyses. Specific antibodies of the following proteins and phosphorylations were used: Lats1, Lats2,
phospho-(Thr1079)-Lats1/2, Yap1, phospho-(Ser127)-Yap. A) RT-qPCR analyses: early induction (t = 4 h) of Lats1/2 transcripts and late
transcripts repression of the reporter genes Cyr61 and Ctgf in MEF-wt andMEF-dKO. Dotted lines represent control values in the absence of
AICAR. (*P b .05; **P b .01; ***P b .001). (B-C) Western blot: Lats1/2 were phosphorylated in MEF-dKO (B) and in MEF-wt (C) in response
to AICAR. Lats1 and Lats2 proteins were induced following treatment with AICAR and phosphorylation/inhibition of Yap1/Taz
activities was detected in both cell types.
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AICAR-mediated translocation of YAP1 by siRNA LATS1/2
knockdown approaches, which efficiently reduced the expression
of the corresponding proteins in RPE-1 cells (Figure S4B). In cells
treated with the non-targeting siRNA, AICAR treatment induced the
cytoplasmic delocalization and decrease of the YAP1 protein (Figure
3, C and D). In comparison, delocalization of YAP1 was abolished
when RPE-1 cells were treated with siRNA targeting LATS1/2
mRNA. We concluded that the decrease of the nuclear fraction of
YAP1 under AICAR treatment was dependent on LATS1/2.
Knockdown of LATS1/2 Rescued Proliferation of Human and
Mice Cells Under AICAR Treatment
LATS1/2 being essential for the YAP1/TAZ-mediated effects of
AICAR, we then used the knockdown approach to evaluate the
impact of LATS1/2 activation on AICAR-mediated cytotoxicity.
Cellular viability was measured in MEF-wt and RPE-1 cells treated ornot with AICAR. siRNA knockdown against LATS1/2 induced a
strong decrease of the level of the corresponding proteins in these cells
(Figure S4, B and C) and significantly restored their growth in the
presence of AICAR (Figure 4). The higher resistance of MEF and RPE-1
cells toAICAR treatment is consistentwith the expected effect of LATS1/2,
these protein kinases acting as potent repressors of proliferation through
phosphorylation/inhibition of YAP1 and TAZ oncogenes.Discussion
AICAR is a purine precursor endowed with therapeutic properties
[32]. Its intracellular monophosphorylated form (ZMP) mimics the
binding of AMP to the low energy sensor regulatory enzyme AMPK,
and is therefore widely used as an energy-stress mimicking agonist
[3,33]. Recent studies also pointed to AICAR as a potent modulator
of AMPK-independent functions in mammals. Such effects converge
towards cell growth inhibition and cytotoxicity [2,5,15,16].
Figure 3. Subcellular redistribution of YAP1/TAZ proteins under AICAR treatment depends on LATS1/2. Human RPE-1 cells were seeded at
lowdensity andstimulatedoneday laterwith3 mMAICAR.Subcellular localizationofYAP1andTAZwas thenmonitoredby immunofluorescence.
(A) Representativemicrophotographsof control RPE-1 cells (Ctrl) andof the samecells stimulatedwithAICAR for 4 hor 24 h.DAPI (blue)wasused
to stain cell nuclei. Scale bars: 10 μm. (B)Quantification of the cytosolic and nuclear fractions of YAP1 and TAZ proteins in RPE-1 cells by using the
ImageJ software. At least ten images taken randomly (N 50 cells) were analyzed for each condition and the average intensity of fluorescencewas
reported as a function of time. (C) and (D) siRNAs-mediated knockdown of LATS1/2 impeded the subcellular redistribution of YAP1 in RPE-1 cells.
siRNA-transfected RPE-1 cells were incubated for 8 h with or without 3 mMAICAR. siNT, nontarget siRNA-transfected cells. siLATS1/2, LATS1/2
siRNA-transfected cells. Scale bars: 10 μm. (C) Microphotographs of RPE-1 cells. (D) Quantification of YAP1 in nuclei of RPE-1 cells. Results are
mean values ± SD (ns, P N .05; ***P b .001).
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to AICAR treatment was evidenced in different cell models, offering
appealing perspectives in cancer therapy [6,9].Figure 4. Viability of MEFs and RPE-1 cells is partly restored by inhibit
with a nontarget siRNA (siNT). The influence of siRNA-mediated knock
for two (MEF-wt) or three days (RPE-1) in the presence of AICAR. Re
mean±SDof triplicates. Relative cell proliferationwas set at 100%, corr
P N .05; *P b .05; **P b .01; ***P b .001).By using an unbiased approach, we aimed at identifying cellular
functions that could be modulated by AICAR independently of
AMPK. We carried out a gene expression microarrays analysis usingion of LATS1/2. Cells were either transfected with siRNA Lats1/2, or
down on cell growth was thenmonitored byWST-1 after incubation
sults are representative of three independent experiments and are
esponding to the signal obtainedwith cells transfectedwith siNT. (ns,
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analysis indicated that these cells responded to AICAR treatment
by up-regulating the tumor suppressor genes Lats1 and Lats2, both of
which encode the most downstream protein kinases of the Hippo
cascade. This effect, hereby defined as to the early cell response (~2–4
h) to AICAR, was accompanied with the increase in the
corresponding proteins Lats1/2. Phosphorylation of Lats1 was also
observed on its threonine residue 1079, a molecular marker of its
catalytic activation. In a late (≥ 12 h) cell response to AICAR,
down-regulation of a collection of gene was displayed as a signature of
the repression of Yap1/Taz transcriptional coactivators. These finding
were in good agreement with the fact that AICAR promoted Yap1/
Taz inhibitory phosphorylation as well as their subcellular delocal-
ization. One prominent response of mammalian cells to AICAR is
therefore the downstream activation of the Hippo signaling cascade,
leading to the blockade of Yap1/Taz effector functions. Remarkably,
knockdown of Lats1/2 partially rescued the growth of AICAR-treated
cells, which established that Lats1/2 activity is indeed involved in the
antiproliferative effect of this drug.
Lats1/2 play a central role in tissue growth and size in metazoans
[20,26]. In addition, Lats1/2 (acting as tumor suppressors) and Yap1/
Taz (as proto-oncogenes) are involved at critical stages of tumor
progression [34–38]. Thus, it may come as no surprise that AICAR
interferes with mechanisms linked to the cell cycle, inhibition of
proliferation, decrease of cell migration/invasion, inhibition of the
epithelial–mesenchymal transition (EMT) and induction of apoptosis
(see for example [2,4,5,39,40]). In xenograft models, AICAR
consistently slows tumor progression, inhibits tumor cell invasion and
also expresses anti-angiogenic properties [12,41].
The cellular response to AICAR was observed in MEF-dKO cells
and thus did not require the presence of AMPK. Notably, AICAR
activation in the absence of AMPK did not exactly replicate in
MEF-wt, suggesting that the AMPK pathway could also modulate
LATS and YAP1 activities. Indeed, AMPK was previously shown to
inhibit YAP1 by direct phosphorylation, and was also able to activate
LATS [29,42]. In addition, AICAR-activated AMPK signaling
repressed the transcription of YAP1-regulated genes CTGF and
CYR61 in LATS1/2 double knockdown cells [29,42]. Two parallel
pathways, involving either AMPK or LATS kinases, may therefore
converge to YAP1 inhibition under AICAR treatment. The rapid
post-translational activation (in minutes) of AMPK upon AICAR
binding has however to be distinguished from the transcriptional
activation of LATS1/2 (≥ 2 h) reported here. Interestingly, YAP1
activity is inhibited by both AMPKα1/2 kinases and LATS1/2 kinases
through phosphorylation at distinct sites (YAP-Ser61/Ser94 and
YAP-Ser127, respectively) [29,42], which suggests complementary
downstream functions of AICAR through these two types of regulatory
kinases. Inhibition of YAP1-dependent transcription using paired
signals (i.e. AMPK- and LATS-dependent) may conform physiologi-
cally with the energetic and biosynthetic status of the cells as well as with
the mechanical constraints imposed by their positioning in tissues
[20,43].
These findings broaden our knowledge of AICAR's antitumor
properties. They provide a rationale for the development of
derivatized pharmacological compounds by exploiting the antitumor
properties of the Hippo pathway through activation of LATS1/2.
Caution must be taken however when considering such approaches.
Besides the most characteristic YAP1/TAZ targets, other LATS1/2
kinases substrates were identified, including AMOT, AF6, PARD3Aand NUMA1 proteins whose functions are involved in the
organization of the actin network or in the mitotic spindle orientation
[38]. These, as well as other YAP1/TAZ-independent effects of LATS
[44], arguably enlarge the contribution of AICAR as a multi-target
drug for different tumor types. Besides its opposing effect on tumor
progression through AMPK activation [29,45], an awaited effect of
AICAR, or of derivatized analogs, in therapy would be its ability to
reactivate LATS1/2 in tissues presenting altered upstream signals in a
variety of diseases [34–38].
In conclusion, a transcriptomic approach established that the
Hippo pathway was stimulated under AICAR treatment even in the
absence of AMPK. AICAR activated the tumor suppressors LATS1/2
and, consequently, inhibited the co-transcriptional activators YAP1/
TAZ and downstream-regulated genes in an AMPK-independent
manner. Functionally, the inhibition of cell proliferation by AICAR
was due, in part, to the presence of LATS1/2.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2018.03.006.
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